この製品に関するご意見・ご照会・お問合せはこちら

FDA Approves ELEVIDYS™ as the First Gene Therapy for Duchenne Muscular Dystrophy (DMD)!

On June 22nd, 2023 the FDA provided accelerated approval for ELEVIDYS™, the first gene therapy designed specifically for DMD. This cutting-edge treatment harnesses the power of Adeno-associated virus (AAV) technology to address the root cause of DMD, offering new hope to patients and their families.

DMD is a life-threatening genetic disorder that primarily affects muscle strength and mobility, eventually leading to the need for mobility aids and respiratory support. Currently, there is no known cure for DMD, but various treatments and therapies aim to manage symptoms and improve quality of life for individuals with the condition.

AAV Resources for your Research

Looking for a reliable custom AAV production service?

Look no further than OriGene! Our custom AAV production service provides you with high-quality, purified AAV particles tailored to your specific needs.

Key Features and Benefits

1. Broad Serotype Selection: We offer a wide range of 11 different AAV serotypes, including AAV1, AAV2, AAV3, AAV5, AAV6, AAV7, AAV8, AAV9, AAVrh.10, AAVDJ, and AAV-PHP.eb. This allows researchers to choose the most suitable serotype for their specific application, maximizing transduction efficiency and targeting capabilities.
2. Rapid Turnaround Time: With a fast turnaround time of 2-3 weeks, researchers can quickly obtain their AAV vectors and proceed with their experiments without unnecessary delays.
3. High Titer Guaranteed: We guarantee a competitive titer of > 1x10^13 GC/mL, ensuring researchers receive AAV particles with high viral particle concentrations for efficient transduction and optimal gene expression.

Researchers were also interested in